Set for Sept. 27–28 at the InterContinental New York Times Square, the continuing medical education (CME) conference will feature more than two dozen experts across numerous therapeutic fields. Heading the program will be Stephen D. Silberstein, MD, a professor of neurology and director of the Jefferson Headache Center at Thomas Jefferson University.
“The future of neurological therapeutics looks wonderful. There are new disease treatments that we never even dreamed about, from gene editing to antibodies,” Silberstein said in a news release.
“Please join me in September as we will be having a meeting about the multiple sub-specialties of migraine, epilepsy, stroke, movement disorders, in addition to specific coverage of things like gene therapy, monoclonal antibodies, and even cannabis,” Silberstein added.
Called the International Congress on the Future of Neurology, the two-day conference is directed toward physicians who specialize in neurological disorders, as well as fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in neurological disorder management.
Current knowledge and information on existing and promising therapies will be discussed, as will best ways of treating diseases include MS, Alzheimer’s and related dementia, epilepsy, stroke, movement disorders, headaches and migraines, neuromuscular disorders, and sleep disorders.
Experts will present data, review specific cases, and answer questions. In addition to up-to-date information on pipeline treatments, attendees will learn more about how to diagnose and manage neurological diseases such as MS. Other discussion points include new insights into communication strategies to improve patient outcomes, how to best leverage multidisciplinary care, and how to manage treatment-related adverse reactions.
Depending upon whether interest is in one or both conference days, advance fees range from $49 to $299. To register, please visit this link.
“We are thrilled to announce this new CME two-day congress focusing on neurologic disorders,” said Phil Talamo, president of PER.
“With so many new advancements in the field, and many more upcoming, clinicians need guidance on how to best apply new treatment and management strategies. This meeting will have 25 faculty across all core areas of neurology highlighting new data and sharing best practices in an interactive learning environment,” Talamo added.
According to the National Multiple Sclerosis Society, more than 2.3 million people worldwide are affected by MS.